Sold as Lartruvo. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Olaratumab (sold as Lartruvo), first approved Oct 19, 2016, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| 89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue SarcomaSoft Tissue Sarcoma, PDGFR Alpha Positive Solid Tumours · Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 1 | Recruiting | Aug 5, 2024 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Oct 19, 2016 | LartruvoBLA 761038 · New molecular entity | Eli Lilly And Co | 2 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
